SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs DefenCath could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and sales. Traders dispute how conclusive DaVitas estimate is, pointing to CMSs finalized payment rate and arguing the outlook depends on quarterly calculations and DefenCath uptake.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing RRP treatment has put Precigens PAPZIMEOS under scrutiny, with traders debating whether the new option will erode its market position. Some fear stronger competition, while others point to Precigens first-mover and full-approval advantages and question Inovios ability to commercialize its drug.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by Eylea HD and Dupixent-related collaboration revenue, are driving a sharp breakout to multiyear highs. Traders are broadly bullish on the results and follow-through, while some question whether the gains will hold.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,942,077.7905448. The last known price of Zcash is 1,263.32437248 USD and is up 2.82 over the last 24 hours. It is currently trading on 668 active market(s) with $1,115,981,976.30 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rebound and resilience amid broader crypto weakness and Binance hack fears have traders highlighting its privacy features and speculating about a safe-haven shift into ZEC; some also point to the upcoming NU7 upgrade. Others view the rally as overextended and expect further declines.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is drawing attention after Brazil approved its Valaris merger, which traders see as a step toward closing the deal, alongside recent offshore contract wins and higher day-rate expectations. Bulls anticipate improved scale and a potential short squeeze, while skeptics point to merger-related dilution, debt and the upcoming earnings report.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly results beat expectations, with record refining performance benefiting from tight diesel supplies amid geopolitical disruptions. Traders are broadly positive on the refining-led strength and shareholder returns, while some question whether the unusually strong margins can last.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

FLYs sharp decline is being discussed alongside weakness across the broader market and space stocks, with some traders citing inflation and interest-rate concerns. Others point to uncertainty over Alpha launch timing and execution, while bulls argue the selloff is sector-driven and note a lack of clear negative company news.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report and higher full-year revenue outlook, powered by demand for Mounjaro and Zepbound, have fueled LLYs rally and record highs. Traders are largely positive and cite analyst upgrades, while some question the valuation and point to trimmed profit guidance tied to acquisition-related research charges.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to a fresh 52-week high ahead of an expected quarterly report has traders focused on BRIUMVI growth and whether results can justify the run; some expect an earnings-driven move, while others warn the stock may be priced for a beat. Buyout speculation and possible short covering are also fueling bullish chatter, but no deal is confirmed and the earnings timing remains uncertain.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharply weaker quarterly outlook, driven by soft PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are split between calling the decline an overreaction and buying the dip, and warning that execution problems and continued weakness could bring further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Transcript: Insight Molecular Q2 2026 Earnings Conference Call

Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below.
Benzinga APIs provide real-time access to earnings call transcriptsread more...

Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Monday Sector Leaders: Biotechnology, Oil & Gas Refining & Marketing Stocks

In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.1%. Leading the group were shares of Insight Molecular Diagnostics, up about 22.8% and shares of Replimune...

Insider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Purchases 250,923 Shares of Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. bought 250,923 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was acquired at...

Broadwood Partners, L.P. Buys 250,923 Shares of Oncocyte (NASDAQ:IMDX) Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 250,923 shares of the firm's stock in a transaction that occurred on Monday, April 27th. The stock...

Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Acquires 280,381 Shares

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 280,381 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were...

Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Purchases 38,880 Shares

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. bought 38,880 shares of the stock in a transaction dated Friday, April 24th. The stock was purchased at an...

Broadwood Partners, L.P. Purchases 40,114 Shares of Oncocyte (NASDAQ:IMDX) Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock in a transaction that occurred on Friday, April 17th. The shares were...

Oncocyte (NASDAQ:IMDX) Major Shareholder Purchases $352,096.65 in Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 102,057 shares of Oncocyte stock in a transaction on Thursday, April 16th. The stock was acquired at...

Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires $157,877.20 in Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 40,690 shares of Oncocyte stock in a transaction dated Monday, April 20th. The stock was bought at...

Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.

Insight Molecular Diagnostics Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.96
Prev Close	$3.18
Open	$3.12
Dividend Yield	0.00%
50-Day Moving Average	$3.62
Beta	0.85
Avg. Volume	280,552.42
PE Ratio	-1.99

52-Week High	$8.51
52-Week Low	$2.42
Market Capitalization	$104.06M
EPS (Annual)	-$1.65
Price to Book	-4.53
Revenue Per Employee	$69,913.79

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMDX Fundamentals